Timing note: Waters scheduled its second-quarter call for Tuesday, August 4, 2026, at 8:00 a.m. ET. Under the stated current date, that is today rather than tomorrow. No Q2 release was available in the documents reviewed, so this preview treats the report as still pending.
This is Waters’ second report since closing the acquisition of BD’s Biosciences and Diagnostic Solutions businesses on February 9. Q1 was an unusually strong opening quarter: legacy Waters delivered double-digit organic growth, the acquired businesses exceeded management’s revenue expectations by $40 million, and adjusted EPS beat the high end of guidance by $0.35.
Consequently, merely meeting Q2 guidance may not be enough to satisfy investors. The central question is whether Q1 marked the beginning of a durable improvement in the combined company—or benefited from extra selling days, shipment timing, easy comparisons and the initial burst of post-close execution.
The report should be judged on four things:
Management’s Q2 guidance provides the most relevant hurdle:
| Metric | Q2 2026 guidance |
|---|---|
| Legacy organic constant-currency growth | 6%–8% |
| Legacy reported revenue | $814M–$829M |
| Acquired Biosciences and Diagnostic Solutions revenue | ~$802M |
| Acquired-business reported growth | ~2.5% |
| Total reported revenue | $1.616B–$1.631B |
| Adjusted diluted EPS | $2.95–$3.05 |
The EPS range represents roughly flat to 3.4% growth, reflecting the full burden of the additional shares and interest expense associated with the transaction. Cost synergies were not expected to contribute materially until Q3.
Full-year guidance entering the report is:
| Metric | FY2026 guidance |
|---|---|
| Legacy organic constant-currency growth | 6.5%–8% |
| Total reported revenue | $6.405B–$6.455B |
| Acquired-business revenue | ~$3.035B |
| Adjusted EBIT margin | 28.2% |
| Adjusted diluted EPS | $14.40–$14.60 |
| Net interest expense | ~$186M |
| Adjusted tax rate | ~16% |
At the August 3 closing price of $374.78, WAT trades at approximately 25.8 times the midpoint of adjusted EPS guidance. That valuation leaves room for upside if management raises its outlook, but it also raises the cost of any evidence that the Q1 acceleration is fading.
Legacy Waters generated $747 million in Q1 revenue, up 11% organically in constant currency. Analytical Sciences grew 12%, including:
The quality of that performance was generally high. LC-MS replacement demand remained strong, chemistry benefited from MaxPeak Premier and bioseparations products, and service growth reflected increased service-plan attachment.
However, Q1 contained approximately four additional working days. Management estimated that this added roughly four percentage points to recurring-revenue growth and about two points to total legacy growth. Q2 also faces a difficult chemistry comparison, including some prior-year pull-forward.
A high-single-digit core result with balanced instrument and recurring growth would be more compelling than a beat driven primarily by large instrument shipments.
The acquired operations produced $520 million during Waters’ Q1 ownership period and exceeded guidance by $40 million. On a full-quarter pro forma basis, the businesses were flat year over year, a major improvement from their Q4 decline. Excluding a $20 million respiratory-testing headwind, pro forma growth was approximately 3%.
Q1 revenue during Waters’ ownership period was $232 million, with estimated growth of 7%. On a full-quarter pro forma basis:
The Q2 question is whether better sales execution and reagent momentum can offset continued pressure in academic instruments and China.
The acquired Diagnostic Solutions business contributed $288 million during the owned period. On a full-quarter pro forma basis:
The respiratory headwind was not expected to recur, while China comparisons should improve in the second half. That creates a favorable setup—but also makes progress increasingly necessary rather than optional.
Management guided the acquired businesses to approximately $802 million of Q2 revenue and 2.5% growth. Investors should distinguish between:
A result above $802 million, accompanied by stronger funnels and stable or better full-year assumptions, would validate the early turnaround. A shortfall would raise doubts about whether Q1’s $40 million beat was repeatable.
Waters entered Q2 targeting:
The company expected restructuring savings to begin benefiting the income statement in Q3. This quarter’s call should therefore provide the last major operational checkpoint before those savings become visible.
Management has highlighted:
Notably, management said incremental pricing benefits and improved reagent-rental contract compliance were not embedded in guidance. An initial review found roughly 700 of 1,600 U.S. Diagnostic Solutions contracts out of compliance, representing a double-digit-million-dollar annual opportunity.
Investors should be wary if management discusses activity metrics but provides little evidence of revenue conversion or realized savings.
Several product initiatives could influence the trajectory beyond Q2.
The next-generation blood-culture platform received European CE marking ahead of schedule. Waters identified approximately 12,000 BACTEC systems potentially ripe for replacement; more than half are over five years old and more than one-quarter are over ten years old.
The call should clarify:
Waters planned to begin local manufacturing of key flow products in China during Q3. This is intended to improve tender access and reduce export complexity.
That initiative matters because the company experienced a stark divergence in Q1:
The most useful update would include order activity, tender qualification and a realistic revenue-contribution timetable—not merely confirmation that localization remains on schedule.
Investors should also listen for adoption commentary around:
Q1 adjusted gross margin was 54.7% and adjusted operating margin was 23.6%, both approximately 200 basis points better than management had expected. Those results came before material cost-synergy benefits.
Full-year adjusted EBIT-margin guidance of 28.2% implies substantial second-half improvement. Investors should focus less on the absolute Q2 margin—which is still burdened by integration and financing—and more on whether management can credibly bridge from Q2 to the FY target.
Important variables include:
Management previously said it had operational measures intended to offset higher freight and input costs. Any erosion in that confidence could offset an otherwise solid revenue result.
The transaction dramatically changed Waters’ balance sheet. At the end of Q1, the company had:
Q1 cash flow was distorted by transaction payments and the timing of settlements with BD. Still, investors need to see working capital begin to normalize.
Accounts receivable and inventory increased materially after the acquisition, while the company remains dependent on BD for certain billing, collection and transition services. The TSA can run for as long as three years and costs approximately $90 million annually.
Adjusted EPS is the market’s principal earnings metric, but cash conversion will increasingly determine the credibility of the combined company’s value-creation plan.
This would support the argument that Waters can progress toward high-single-digit pro forma growth, annual margin expansion of at least 100 basis points and mid-teens adjusted EPS growth.
Given the strong Q1 beat and current valuation, this outcome may produce only a modestly positive reaction.
That combination would challenge both the acquired-business turnaround and the premium earnings multiple.
The reported Q2 numbers matter, but the second-half bridge matters more. Waters has already demonstrated that management can rapidly improve commercial activity in the acquired businesses. It now needs to prove that those actions translate into repeatable growth, margin expansion and cash generation.
The cleanest positive report would combine:
With the shares trading around 26 times adjusted EPS guidance and having rallied sharply after Q1, expectations are no longer low. Investors are likely to reward a guidance raise backed by improving acquired-business fundamentals, but may look through a headline beat if it lacks stronger second-half evidence.